LabGenomics Co (084650) Fair Value & Analysis
Healthcare · KR · Market cap 81.8B KRW
Fair value as of: Jul 6, 2026
From 1 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 6,551 KRW to 854.05 KRW (−87.0%) since Jun 24, 2026. Share price −22.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 697.00 KRW – 2,865 KRW · fair‑value band 637.35 KRW – 1,275 KRW · the 697.00 KRW price screens below the 854.05 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
LabGenomics Co (084650) currently trades at 697.00 KRW, while our model-based Fair Value estimate is 854.05 KRW — implying the stock looks roughly 22.5% undervalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, LabGenomics Co generated revenue of 187B KRW at a net margin of 39.7%. Revenue declined 54.1% year over year. Net debt stands at 41.9B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 637.35 KRW (bear case) to 1,275 KRW (bull case); at 697.00 KRW, the current price sits within that range. The share trades about 76% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -42% fair-value upside — at 23%, 084650 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
LabGenomics Co reported revenue of 88.2B KRW in FY2025 versus 202B KRW in FY2021, a compound −18.8%/yr. Reported net income was −64.4B KRW in FY2025.
Is 084650 fairly valued? → Check now
Similar stocks
10 more Healthcare Providers & Services stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 0NQH 0NQH | €0.1260 | €0.0600 | -52% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| UnitedHealth Group UNH | 7,169 MXN | 5,226 MXN | -27% |
| Roche Holding ROGN | 7,050 MXN | 5,381 MXN | -24% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| AstraZeneca PLC AZN | kr 1,742 | kr 955.95 | -45% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| Amgen Inc AMGN | 6,170 MXN | 3,666 MXN | -41% |
| Novo Nordisk A/S, NVON | 733.11 MXN | 230.36 MXN | -69% |
| Thermo Fisher Scientific Inc TMO | 8,423 MXN | 3,691 MXN | -56% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is LabGenomics Co (084650) undervalued?
What is the fair value of 084650?
What is the quality score of 084650?
What is the revenue of LabGenomics Co (084650)?
What is the net profit margin of 084650?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.